Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines

Biological Chemistry

Volumn 389, Issue 5, 2008, Pages 569-577

  Howard, M Keith ^a   Kistner, Otfried ^a   Barrett, P Noel ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

Author keywords

Cross protection; Influenza virus; Vero cells; Whole virus vaccine

Indexed keywords

ALUMINUM HYDROXIDE; CROSS REACTING ANTIBODY; IMMUNOLOGICAL ADJUVANT; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS A H5N1 VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS HEMAGGLUTININ;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL MODEL; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; VACCINE PRODUCTION; VERO CELL; VIROGENESIS; VIRUS STRAIN; WILD TYPE;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CELL LINE; CERCOPITHECUS AETHIOPS; DISEASE OUTBREAKS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FERMENTATION; GUINEA PIGS; HEMAGGLUTINATION TESTS; HUMANS; IMMUNODIFFUSION; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; NEUTRALIZATION TESTS; VERO CELLS;

ANIMALIA; AVES; ORTHOMYXOVIRIDAE;

EID: 45749132153     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2008.060     Document Type: Article

References (35)

1. Bresson, J.L., Perronne, C., Launay, O., Gerdil, C., Saville, M., Wood, J., Höschler, K., and Zambon, M.C. (2006). Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367, 1657-1664.
2. Genzel, Y., Olmer, R.M., Schäfer, B., and Reichl, U. (2006). Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media. Vaccine 24, 6074-6087.
3. Govorkova, E.A., Murti, G., Meignier, B., de Taisne, C., and Webster, R.G. (1996). African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses. J. Virol. 70, 5519-5524.
4. Govorkova, E.A., Webby, R.J., Humberd, J., Seiler, J.P., and Webster, R.G. (2006). Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J. Infect. Dis. 194, 159-167.
5. Guan, Y., Poon, L.L., Cheung, C.Y., Ellis, T.M., Lim, W., Lipatov, A.S., Chan, C.H., Sturm-Ramirez, K.M., Cheung, C.L., Leung, Y.H., et al. (2004). H5N1 influenza: a protean pandemic threat. Proc. Natl. Acad. Sci. USA 101, 8156-8161.
6. Hardy, C.T., Young, S.A., Webster, R.G., Naeve, C.W., and Owens, R.J. (1995). Egg fluids and cells in the corioallantoic membrane of embryonated chicken eggs can select different variants of Influenza A (H3N2) virus. Virology 211, 302-306.
7. Horimoto, T., Fukuda, N., Iwatsuki-Horimoto, K., Guan, Y., Lim, W., Peiris, M., Sugii, S., Odagiri, T., Tashiro, M., and Kawaoka, Y. (2004). Antigenic differences between H5N1 human influenza viruses isolated in 1997 and 2003. J. Vet. Med. Sci. 66, 303-305.
8. Kapteyn, J.C., Saidi, M.D., Dijkstra, R., Kars, C., Tjon, C.M.S-K., Weverling, G.J., de Vocht, M.L., Kompier, R., van Montfort, B.A., Guichoux, J.Y., et al. (2006). Haemagglutinin quantification and identification of influenza A&B strains propagated in PER.C6 cells: a novel RP-HPLC method. Vaccine 24, 3137-3144.
9. Katz, J.M. and Webster, R.G. (1989). Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J. Infect. Dis. 160, 191-198.
10. Kistner, O., Barrett, P.N., Mundt, W., Reiter, M., Schober-Bendixen, S., and Dorner, F. (1998). Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 9/10, 960-968.
11. Kistner, O., Barrett, P.N., Mundt, W., Reiter, M., Schober-Bendixon, S., Eder, G., and Dorner, F. (1999). Development of a Vero cell-derived influenza whole virus vaccine. Dev. Biol. Stand. 98, 101-110.
12. Kistner, O., Howard, M.K., Spruth, M., Wodal, W., Brühl, P., Gerencer, M., Crowe, B.A., Savidis-Dacho, H., Livey, I., Reiter, M., et al. (2007). Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25, 6028-6036.
13. Lin, J., Zhang, J., Dong, X., Fang, H., Chen, J., Su, N., Gao, Q., Zhang, Z., Liu, Y., Wang, Z., et al. (2006). Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza a (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368, 991-997.
14. Lipatov, A.S., Webby, R.J., Govorkova, E.A., Krauss, S., and Webster, R.G. (2005). Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. J. Infect. Dis. 191, 1216-1220.
15. Lu, X., Tumpey, T.M., Morken, T., Zaki, S.R., Cox, N.J., and Katz, J.M. (1999). A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J. Virol. 73, 5903-5911.
16. Mase, M., Tsukamoto, K., Imada, T., Imai, K., Tanimura, N., Nakamura, K., Yamamoto, Y., Hitomi, M., Kira, T., Nakai, T., et al. (2005). Characterization of H5N1 influenza A viruses isolated during the 2003-2004 influenza outbreaks in Japan. Virology 332, 167-176.
17. Montagnon, B.J., Fanget, B., and Nicolas, A.J. (1987). The large-scale cultivation of Vero cells in microcarrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine. Dev. Biol. Stand. 47, 55-64.
18. Palker, T., Kiseleva, I., Johnston, K., Su, Q., Toner, T., Szymkoviak, C., Kwan, W.S., Rubin, B., Petrukhin, L., Wlochowski, J., et al. (2004). Protective efficacy of intranasal cold-adapted influenza A/New Caledonia/20/99 (H1N1) vaccines comprised of egg- or cell culture-derived reassortants. Virus Res. 105, 183-194.
19. Plotkin, S.A., Murdin, A., and Vidor, E. (1999). Inactivated polio vaccine. In: Vaccines, 3rd edn, S.A. Plotkin and W.A. Orenstein, eds. (Philadelphia, PA, USA: W.B. Saunders), pp. 345-363.
20. Reed, L.J. and Muench, H. (1938). A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-497.
21. Robertson, J.S. (1993). Clinical influenza virus and the embryonated hen's eggs. Rev. Med. Virol. 3, 97-108.
22. Robertson, J.S., Bootman, J.S., Newman, R., Oxford, J.S., Daniels, R.S., Webster, R.G., and Schild, G.C. (1987). Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A (H1N1) virus. Virology 160, 31-37.
23. Rowe, P.M. (1995). Pandemic influenza (un)preparedness described. Lancet 346, 1699.
24. Schild, G.C., Oxford, J.S., De Jong, J.C., and Webster, R.G. (1983). Evidence for host-cell selection of influenza virus antigenic variants. Nature 303, 706-709.
25. Stephenson, I. (2006). H5N1 vaccines: how prepared are we for a pandemic? Lancet 368, 965-966.
26. Suguitan, A.L. Jr., McAuliffe, J., Mills, K.L., Jin, H., Duke, G., Lu, B., Luke, C.J., Murphy, B., Swayne, D.E., Kemble, G., and Subbarao, K. (2006). Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 3, e360.
27. Treanor, J.J., Wilkinson, B.E., Masseoud, F., Hu-Primmer, J., Battaglia, R., O'Brien, D., Wolff, M., Rabinovich, G., Blackwelder, W., and Katz. J.M. (2001). Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19, 1732-1737.
28. Treanor, J.J., Campbell, J.D., Zangwill, K.M., Rowe, T., andWolff, M. (2006). Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354, 1343-1351.
29. Van Riel, D., Munster, V.J., de Wit, E., Rimmelzwaan, G.F., Fouchier, R.A., Osterhaus, A.D., and Kuiken, T. (2006). H5N1 virus attachment to lower respiratory tract. Science 312, 399.
30. Wood, J.M., Schild, G.C., Newman, R.W., and Seagroatt, V. (1977). An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J. Biol. Stand. 5, 237-247.
31. World Health Organisation (2005a). WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines (Geneva, Switzerland: World health Organization).
32. World Health Organisation (2005b). Evolution of H5N1 avian influenza viruses in Asia. Emerg. Inf. Dis. 11, 1515-1521.
33. World Health Organisation (2006). Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines (http://www.who.int/csr/disease/avian_influenza/ guidelines/).
34. Yen, H.-L., Lipatov, A.S., Ilyushina, N.A, Govorkova, E.A., Franks, J., Yilmaz, N., Douglas, A., Hay, A., Krauss, S., Rehg, J.E., et al. (2007). Inefficient transmission of H5N1 influenza viruses in a ferret contact model. J. Virol. 81, 6890-6898.
35. Youil, R., Su, Q., Toner, T.J., Szymkowiak, C., Kwan, W.-S., Rubin, B., Petrukhin, L., Kiseleva, I., Shaw, A.R., and Di-Stefano, D. (2004). Comparative study of influenza virus replication in Vero and MDCK cell lines. J. Virol. Methods 120, 23-31.